ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2443

Prevalence Of Coronary Heart Disease In Spondyloarthopathies  may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center

Trayton Mains1 and Vikas Majithia2, 1University of Mississippi Medical Center, Jackson, MS, 2G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), coronary artery disease, Psoriatic arthritis, risk and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose: An increased prevalence of cardiovascular disease (CVD) and coronary heart disease (CHD) has been reported in patients with spondyloarthritides (SpA). This study investigated the prevalence of CVD risk factors, CVD including CHD and stroke in veterans with SpA (including PsA, Ankylosing Spondylitis (AS), and reactive arthritis (ReA) at the Jackson VAMC.

Methods: A retrospective chart review using ICD-9 codes for PsA, AS, and ReA was performed at Jackson, VAMC. Data including age, race, gender, medications, ESR, CRP, lipid panel, HbA1c, 25-OH Vitamin D level, hypertension (HTN), smoking, statin use, and CVD events were tabulated. Age, sex and race matched controls were selected from VA clinics with a 2:1 ratio. Comparisons of CHD, stroke, and CVD risk factors were made to a matched population from the American Heart Association data, as well as the CDC’s 2003-2004 evaluation of chronic disease in Male veterans. Risk factors included smoking, dyslipidemia (DLD), HTN, and diabetes Mellitus (DM). Prevalence ration and odds ratio were calculated by standard method. Statistical significant (alpha <0.05) was calculated using Chi-square and Fisher's exact test.

Results: There were 81 patients, 79 were male and 2 female. With a mean age of patients with PsA, AS, and ReA being 61,8, 60.4, and 56, respectively. There was a significant increase in the prevalence of CHD and its risk factors in the SpA, PsA, and AS patients when compared with the AHA data, and General Male vets from the 2003-04-control population. When compared to the matched controls, prevalence was increased in the overall SpA, PsA and AS patients but did not achieve statistical significance suggesting increased an risk despite having slightly lower prevalence of risk factors. Also, in both SpA and matched controls population there was an increased prevalence of these risk factors, when compared to the AHA and national data. There was insufficient number of black patients in the cohort to assess effect of ethnicity.

Conclusion: Our results suggest that patients with SpA have an increased risk of developing CHD as well its risk factors. Our study is unique as increased risk and it quantification have not been previously reported in the U.S. veteran population. The increased CHD risk attributable to the increased prevalence of risk factors cannot be determined in this study but has been suggested to be over and above them.

Table 1 CHD comparison among spondyloarthropathies and 3 controls.

CHD

%

SpA

PsA

AS

ReA

%

 

26.9

29.3

30.4

14.2

AHA Controls

9.1

PR= 2.96

OR= 3.72

p-value= 0.002

PR= 3.21

OR= 4.18

p-value=0.003

PR= 3.34

OR= 4.42

p-value= 0.01

PR= 1.56

 

General Male Veterans

11.5

PR= 2.34

OR= 2.83

p-value=0.01

PR= 2.55

OR= 3.18

p-value= 0.04

PR= 2.64

OR= 3.36

p-value=0.05

PR= 1.23

 

Matched Controls

18.6

PR= 1.45

OR= 2.83

p-value – NS

PR= 1.57

OR= 3.18

p-value- NS

PR= 1.63

OR= 3.36

p-value- NS

PR= 0.76

 

Table 2 CHD Risk Factors

 

AHA Controls (1) (%)

General Male Veterans (2) %

Matched Controls (3) %

SpA (%)

PsA (%)

AS (%)

ReA (%)

DM

PR

 

7.6

13.6

29.5

24.7

3.25

1.81

0.84

22.7

2.99

1.67

0.77

26.1

3.43

1.92

0.88

28.6

3.76

2.10

0.97

HTN

PR

 

34.4

 

41.2

66

70.4

2.05

1.71

1.07

70.5

2.05

1.71

1.07

73.9

2.15

1.79

1.12

64.3

1.87

1.56

0.97

DLD

PR

 

45.2

44.6

69

60.5

1.34

1.36

0.88

69.8

1.54

1.57

1.01

56.5

1.25

1.27

0.82

42.5

0.95

0.96

0.62

Smoking

PR

 

23.1

22.8

63.1

62.7

2.71

1.50

0.99

62.5

2.71

1.54

0.99

56.5

2.45

0.87

0.9

75

3.25

1.83

1.19

Family Hx

PR

 

 

34.1

27.8

0.87

25

0.73

36.4

1.07

21.4

0.63

 


Disclosure:

T. Mains,
None;

V. Majithia,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-coronary-heart-disease-in-spondyloarthopathies-may-be-increased-due-to-higher-prevalence-of-risk-factors-as-well-as-the-disease-itself-a-retrospective-analysis-at-single-va-medica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology